RDY logo

DR. REDDY'S LABORATORIES-ADR

RDYNYSE
πŸ† #703 by market capEarnings Jan 19US Equity
β€”β€”
Quote unavailable
πŸ””
Track RDY
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$12.37B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
8.6%
Slowing
πŸ“ŠGross Margin
49.5%
Healthy
πŸ’΅FCF Margin
3.5%
Moderate
βš–οΈP/S Ratio
3.5x
Fair
Otter Score
80
Strong
No chart data available for RDY.

Trading Snapshot

Day Range
β€”
52-Week Range
$11.36 – $15.67
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
830.8M
Next Earnings
2027-01-19

Fundamentals Snapshot

Annual Revenue
$353.47B
Last Q Revenue
$86.59B
P/E Ratio
41.4
P/S Ratio
3.5x
EPS (TTM)
$33.58
Dividend Yield
0.58%
Dilution (1yr)
+0.0%
RDY logo

DR. REDDY'S LABORATORIES-ADR

RDY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$353.5Bβ–² +8.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
52.8%β–Ό βˆ’9.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$48.9Bβ–Ό βˆ’32.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$32.1Bβ–² +166.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
833.3Mβ–² +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$59.3Bβ–Ό βˆ’$10.2B YoY
StockOtter Β· stockotter.space

About DR. REDDY'S LABORATORIES-ADR

Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
80/100

Analyst Ratings

β“˜
Consensus
Buy
42 analysts
Strong Buy11
Buy15
Hold9
Sell7
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.